Elanco Animal Health Files 2024 Proxy Statement

TL;DR

Elanco's proxy statement is out for the May 30th meeting - vote on directors & auditors.

AI Summary

Elanco Animal Health Inc. filed its definitive proxy statement (DEF 14A) on April 19, 2024, for its annual meeting on May 30, 2024. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: low — A DEF 14A filing is a standard regulatory document providing information to shareholders and does not inherently represent new financial risk.

Key Numbers

• DEF 14A — Filing Type (Definitive Proxy Statement)

Key Players & Entities

• Elanco Animal Health Inc. (company) — Registrant
• 0001140361-24-020680 (filing_id) — Accession Number
• 20240419 (date) — Filing Date
• 20240530 (date) — Meeting Date

FAQ

From the Filing

0001140361-24-020680.txt : 20240419 0001140361-24-020680.hdr.sgml : 20240419 20240419080046 ACCESSION NUMBER: 0001140361-24-020680 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20240530 FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24855649 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 DEF 14A 1 edge20015633x2_def14a.htm DEF 14A     UNITED STATES  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A   Proxy Statement Pursuant to Section 14(a) of the   Securities Exchange Act of 1934       Filed by the Registrant ☒ ​ ​ Filed by a Party other than the Registrant  ☐   Check the appropriate box:   ☐ ​ Preliminary Proxy Statement ☐ ​ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ ​ Definitive Proxy Statement ☐ ​ Definitive Additional Materials ☐ ​ Soliciting Material Pursuant to §240.14a-12   Elanco Animal Health Incorporated   (Name of registrant as specified in its charter)   (Name of person(s) filing proxy statement, if other than the registrant)   Payment of Filing Fee (Check all boxes that apply): ☒ ​ No fee required. ☐ ​ Fee paid previously with preliminary materials. ☐ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.        Letter from our Board of Directors   Dear Shareholders,   Since Elanco’s launch as an independent company five years ago, the Board of Directors has taken decisive actions to help Elanco mature into a company now positioned to deliver sustainable, profitable growth over the long term. Along with that maturity, the Board and company leadership have enacted and proposed a number of governance enhancements that promote accountability and align with best-practice shareholder expectations.   Shareholder-Aligned Governance Enhancements in Response to Feedback   The Board is committed to listening to and responding to shareholder feedback. In 2022, the company eliminated the supermajority vote requirements to amend the Company’s Articles of Incorporation and Bylaws. As the company continues to progress, in this proxy statement, the Board is seeking shareholder approval to enact further governance enhancements:   ●         Commence a process to declassify the Board of Directors; ●         Adopt a majority vote standard for uncontested elections of directors; ●         Allow shareholders to amend the Company’s Bylaws; and ●         Allow shareholders under certain circumstances to call special meetings of shareholders.   The Board values our shareholders’ opinions and appreciates their feedback which has informed our actions. In the past year, members of the Board engaged with investors representing approximately 50% of our outstanding shares and we look forward to maintaining this two-way dialogue.   Board Leadership Changes   As announced in January, the Board has selected Lawrence E. Kurzius to be the next Chairman at the conclusion of the 2024 annual meeting. Lawrence has been an independent direc